| Not Yet Recruiting | DaxibotulinumtoxinA for Blepharospasm NCT07489430 | University of Pennsylvania | Phase 2 |
| Completed | Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin NCT05103202 | University of Texas Southwestern Medical Center | — |
| Completed | Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm NCT05027997 | Addex Pharma S.A. | Phase 2 |
| Unknown | Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm NCT04939909 | Second Affiliated Hospital, School of Medicine, Zhejiang University | EARLY_Phase 1 |
| Completed | Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm NCT04423341 | Silkiss Eye Surgery | Phase 2 / Phase 3 |
| Unknown | A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome NCT04618887 | Peking University People's Hospital | — |
| Completed | Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia NCT03938363 | University Hospital, Grenoble | N/A |
| Unknown | Wumeiwan Jiawei Fang Use in Patients With Blepharospasm NCT05618470 | China Academy of Chinese Medical Sciences | Phase 2 / Phase 3 |
| Terminated | Photic Blink Reflex in People With Blepharospasm and Increased Blinking NCT03263000 | National Institute of Neurological Disorders and Stroke (NINDS) | — |
| Unknown | HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions NCT03184597 | Second Affiliated Hospital of Guangzhou Medical University | N/A |
| Completed | Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm NCT02947815 | Daewoong Pharmaceutical Co. LTD. | Phase 2 / Phase 3 |
| Completed | Blepharospasm Tools NCT02780336 | Emory University | — |
| Unknown | Two Different Surgical Methods of Blepharospasm NCT02765113 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Completed | An RCT of a Patient-initiated Treatment Service for BEB and HFS NCT02577224 | Moorfields Eye Hospital NHS Foundation Trust | N/A |
| Completed | A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm NCT02245958 | Allergan | — |
| Completed | Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm NCT03508882 | The University of Hong Kong | Phase 4 |
| Unknown | Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm NCT02327728 | YangHui | N/A |
| Completed | A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm NCT01814774 | Allergan | — |
| Completed | Blepharospasm Patient Survey for Patients With Blepharospasm NCT01686061 | Merz Pharmaceuticals GmbH | — |
| Unknown | Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial NCT01546805 | St. Joseph's Healthcare Hamilton | N/A |
| Completed | Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States NCT01287247 | Merz North America, Inc. | — |
| Completed | A Mechanical Device for Blepharospasm NCT03269123 | Oxford University Hospitals NHS Trust | N/A |
| Completed | MDs on Botox Utility (MOBILITY) NCT00535938 | Allergan | — |
| Terminated | Blepharospasm Short Interval NCT00507637 | Merz Pharmaceuticals GmbH | Phase 2 |
| Completed | Brain Changes in Blepharospasm NCT00500799 | National Institute of Neurological Disorders and Stroke (NINDS) | — |
| Completed | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm NCT00406367 | Merz Pharmaceuticals GmbH | Phase 3 |
| Completed | Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm NCT00761592 | Allergan | Phase 4 |
| Completed | Brain Stimulation to Treat Blepharospasm or Meige Syndrome NCT00411255 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |
| Completed | Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm NCT00682760 | Pacific Pharmaceuticals | Phase 3 |
| Completed | Post Marketing Surveillance Study of Dysport NCT00210431 | Ipsen | — |
| Completed | Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm NCT00234507 | Ipsen | Phase 2 |
| Completed | Mexiletine for the Treatment of Focal Dystonia NCT00001784 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |